Aromatase
inhibitors as first-line therapy of metastatic disease
Interview
with Neil Love, MD from Breast Cancer Update for Medical Oncologists,
Program 5 2000
Play
Audio Below:
The
data that’s emerging certainly might suggest that an aromatase
inhibitor certainly is the equivalent, and some preliminary data
would suggest might be the superior to tamoxifen. I think that brings
up the legitimate question as to whether or not the champ for the
last 20 years in fact is about to go down before a new contender.
I think it’s reasonably possible that aromatase inhibitors,
as a class, may be superior to tamoxifen. And, I think that has
profound implications, not only for the metastatic setting, but
certainly for the adjuvant setting and possibly for the setting
of chemo-prevention.
Formestane
is feasible and effective in elderly breast cancer patients with
comorbidity and disability. Venturino,
A.; Comandini, D.; Granetto, C.; Audisio, R. A.; Castiglione, F.;
Rosso, R., and Repetto, L. (Reprint available from: Venturino A
PO S Lazzaro, Via P Belli 26 I-12051 Alba CN Italy). Breast Cancer
Research & Treatment. 62(3):217-222, 2000 Aug. In process
Critique
of survival update analysis from two phase III anastrozole clinical
trials. Buzdar, A. U.; Wood; Wolter; Vogel; Bland, and Ravdin. Annals
of Surgical Oncology. 6(8 Suppl S):8S-11S, 1999 Dec. No abstract
Letrozole:
Which dose to be used? Buzdar, A. U. Journal of Clinical Oncology. 18(8):1802-1803,
2000 Apr. No abstract
